{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T17:15:45Z","timestamp":1793121345478,"version":"4.5.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003645","name":"National Cancer Center","doi-asserted-by":"publisher","award":["NCC202425002"],"award-info":[{"award-number":["NCC202425002"]}],"id":[{"id":"10.13039\/501100003645","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019018","name":"Chinese Academy of Medical Sciences Initiative for Innovative Medicine","doi-asserted-by":"publisher","award":["T-B-074"],"award-info":[{"award-number":["T-B-074"]}],"id":[{"id":"10.13039\/501100019018","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.lungcan.2026.109463","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T15:13:52Z","timestamp":1779203632000},"page":"109463","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Study on NGS-based molecular profiling of malignant pleural effusion supernatant cfDNA in guiding targeted therapy for non-small cell lung cancer"],"prefix":"10.1016","volume":"217","author":[{"given":"Yuan","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuo","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Meng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi-Han","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Hua","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-Xiang","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin-Lin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Qin","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Hui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10066","key":"10.1016\/j.lungcan.2026.109463_b0005","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0140-6736(16)30958-8","article-title":"Lung cancer: current therapies and new targeted treatments","volume":"389","author":"Hirsch","year":"2017","journal-title":"Lancet (london, England)"},{"issue":"6","key":"10.1016\/j.lungcan.2026.109463_b0010","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1007\/s00408-020-00407-5","article-title":"Update 2020: management of non-small cell lung cancer","volume":"198","author":"Alexander","year":"2020","journal-title":"Lung"},{"issue":"1","key":"10.1016\/j.lungcan.2026.109463_b0015","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1186\/s12885-024-12520-2","article-title":"Liquid-based cytology specimens for next-generation sequencing in lung adenocarcinoma: challenges and evaluation of targeted therapy","volume":"24","author":"Xiao","year":"2024","journal-title":"BMC Cancer"},{"issue":"12","key":"10.1016\/j.lungcan.2026.109463_b0020","first-page":"8813","article-title":"Detection of EGFR mutation in supernatant, cell pellets of pleural effusion and tumor tissues from non-small cell lung cancer patients by high resolution melting analysis and sequencing","volume":"7","author":"Lin","year":"2014","journal-title":"Int. J. Clin. Exp. Path."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109463_b0025","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00016-2019","article-title":"Cell-free DNA in the supernatant of pleural effusion can be used to detect driver and resistance mutations, and canguide tyrosine kinase inhibitor treatment decisions","volume":"5","author":"Hummelink","year":"2019","journal-title":"ERJ Open Res"},{"issue":"4","key":"10.1016\/j.lungcan.2026.109463_b0030","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1111\/1759-7714.13006","article-title":"Malignant pleural effusion supernatant is an alternative liquid biopsy specimen for comprehensive mutational profiling","volume":"10","author":"Guo","year":"2019","journal-title":"Thorac Cancer"},{"issue":"19","key":"10.1016\/j.lungcan.2026.109463_b0035","doi-asserted-by":"crossref","first-page":"5532","DOI":"10.7150\/thno.34070","article-title":"Tumor-derived DNA from pleural effusion supernatant as a promising alternative to tumor tissue in genomic profiling of advanced lung cancer","volume":"9","author":"Tong","year":"2019","journal-title":"Theranostics"},{"key":"10.1016\/j.lungcan.2026.109463_b0040","unstructured":"National Comprehensive Cancer Network. The NCCN clinical practice guidelines in oncology for non-small cell lung cancer (version 3. 2019).https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1450. Accessed Jan 20, 2019."},{"issue":"3","key":"10.1016\/j.lungcan.2026.109463_b0045","doi-asserted-by":"crossref","first-page":"276","DOI":"10.11613\/BM.2012.031","article-title":"Interrater reliability: the kappa statistic","volume":"22","author":"McHugh","year":"2012","journal-title":"Biochemia Medica"},{"issue":"6","key":"10.1016\/j.lungcan.2026.109463_b0050","doi-asserted-by":"crossref","first-page":"668","DOI":"10.21037\/tlcr.2018.09.23","article-title":"Measuring tumor mutation burden in non-small cell lung cancer: tissue versus liquid biopsy","volume":"7","author":"Fenizia","year":"2018","journal-title":"Transl Lung Cancer Res"},{"issue":"2","key":"10.1016\/j.lungcan.2026.109463_b0055","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.lungcan.2026.109463_b0060","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.7150\/ijms.52306","article-title":"Distinct profile of cell-free DNA in malignant pleural effusion of non-small cell lung cancer and its impact on clinical genetic testing","volume":"18","author":"Yu","year":"2021","journal-title":"Int. J. Med. Sci."},{"issue":"2","key":"10.1016\/j.lungcan.2026.109463_b0065","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0089946","article-title":"Malignant pleural effusion supernatants are substitutes for metastatic pleural tumor tissues in EGFR mutation test in patients with advanced lung adenocarcinoma","volume":"9","author":"Liu","year":"2014","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.lungcan.2026.109463_b0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2020.100784","article-title":"Gene alterations in paired supernatants and precipitates from malignant pleural effusions of non-squamous non-small cell lung cancer","volume":"13","author":"Li","year":"2020","journal-title":"Transl. Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2026.109463_b0075","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1001\/jamaoncol.2022.6109","article-title":"Testing for EGFR variants in pleural and pericardial effusion cell-free DNA in patients with non-small cell lung cancer","volume":"9","author":"Lee","year":"2023","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.lungcan.2026.109463_b0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115224","article-title":"Enhanced detection of actionable mutations in NSCLC through pleural effusion cell-free DNA sequencing: a prospective study","volume":"217","author":"Wang","year":"2025","journal-title":"Eur. J. Cancer"},{"issue":"23","key":"10.1016\/j.lungcan.2026.109463_b0085","doi-asserted-by":"crossref","first-page":"5772","DOI":"10.1158\/1078-0432.CCR-16-1231","article-title":"Detection of therapeutically targetable driver and resistance mutations in lung cancer patients by next-generation sequencing of cell-free circulating tumor DNA","volume":"22","author":"Thompson","year":"2016","journal-title":"Clinical Cancer Res. off. J. Am. Assoc. for Cancer Res."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109463_b0090","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2022.2052418","article-title":"Neutrophil extracellular traps induce tumor metastasis through dual effects on cancer and endothelial cells","volume":"11","author":"Jiang","year":"2022","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.lungcan.2026.109463_b0095","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.lungcan.2019.08.004","article-title":"Cytological-negative pleural effusion can be an alternative liquid biopsy media for detection of EGFR mutation in NSCLC patients","volume":"136","author":"Song","year":"2019","journal-title":"Lung Cancer (amsterdam, Netherlands)"},{"key":"10.1016\/j.lungcan.2026.109463_b0100","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1436588","article-title":"Tissue- and liquid-biopsy based NGS profiling in advanced non-small-cell lung cancer in a real-world setting: the IMMINENT study","volume":"14","author":"Sposito","year":"2024","journal-title":"Front. Oncol."},{"issue":"4","key":"10.1016\/j.lungcan.2026.109463_b0105","article-title":"Trends in molecular testing of lung cancer in mainland People's Republic of China over the decade 2010 to 2019","volume":"2","author":"Li","year":"2021","journal-title":"JTO Clin. Res. Rep."},{"issue":"3","key":"10.1016\/j.lungcan.2026.109463_b0110","doi-asserted-by":"crossref","first-page":"321","DOI":"10.5858\/arpa.2017-0388-CP","volume":"142","author":"Lindeman","year":"2018","journal-title":"Arch. Pathol. Lab. Med."},{"issue":"4","key":"10.1016\/j.lungcan.2026.109463_b0115","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.jmoldx.2020.01.011","article-title":"Molecular profiling for supernatants and matched cell pellets of pleural effusions in non-small-cell lung cancer","volume":"22","author":"Xiang","year":"2020","journal-title":"J. Mol. Diagn."},{"issue":"4","key":"10.1016\/j.lungcan.2026.109463_b0120","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1183\/09031936.00167407","article-title":"Frequent epidermal growth factor receptor gene mutations in malignant pleural effusion of lung adenocarcinoma","volume":"32","author":"Wu","year":"2008","journal-title":"Eur. Respir. J."},{"issue":"9","key":"10.1016\/j.lungcan.2026.109463_b0125","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/gb-2011-12-9-128","article-title":"Exome sequencing: the expert view","volume":"12","author":"Biesecker","year":"2011","journal-title":"Genome Biol."},{"issue":"11","key":"10.1016\/j.lungcan.2026.109463_b0130","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/S1470-2045(17)30608-3","article-title":"Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial","volume":"18","author":"Wu","year":"2017","journal-title":"Lancet Oncol."},{"issue":"6","key":"10.1016\/j.lungcan.2026.109463_b0135","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1093\/annonc\/mdt012","article-title":"Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC)","volume":"24","author":"Chen","year":"2013","journal-title":"Ann. Oncol."},{"issue":"12","key":"10.1016\/j.lungcan.2026.109463_b0140","first-page":"1059","article-title":"Results of EGFR mutations detected in pleural effusion and its clinical significance in 132 patients with advanced non-small cell lung cancer: a retrospective study in a single center","volume":"23","author":"Lu","year":"2020","journal-title":"Zhongguo Fei Ai Za Zhi"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226005246?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226005246?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T13:29:52Z","timestamp":1783085392000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500226005246"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":28,"alternative-id":["S0169500226005246"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109463","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Study on NGS-based molecular profiling of malignant pleural effusion supernatant cfDNA in guiding targeted therapy for non-small cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109463","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"109463"}}